▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #252 by analyst upside · 2026-06-27
ELUT
Elutia Inc.
Healthcare · Market Cap $44M · P/E 0x
ANALYST PRICE TARGET
+400.5%
implied upside to consensus target
Current Price $1.0
Consensus Target $5.0
Bull Target $5.0
Bear Target $5.0
Analysts Covering 1
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $0.5
52-Week High $2.64
YTD Return +55.4%
FUNDAMENTALS
Market Cap $44M
P/E Ratio (TTM) N/A
Forward P/E -0.9x
EPS (TTM) $-0.68
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $12M
Profit Margin 400.2%
52-WEEK RANGE
52-Week Low $0.5
52-Week High $2.64
Current Price $1.0
Bear Target $5.0
Bull Target $5.0
● Now $1.0 ● Target $5.0
TRADING DATA
Avg Volume 106K
YTD Return +55.4%
Analyst Count 1
Consensus Buy
Upside to Target +400.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Elutia Inc. (ELUT) is currently trading at $1.0 with a Wall Street consensus price target of $5.0, implying potential upside of 400.5% over the next 12 months. 1 analysts currently cover ELUT, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $5.0, while the most cautious has a target of $5.0.

ELUT operates in the Healthcare sector with a market capitalisation of $44M. The stock is up 55.4% year-to-date and is currently trading near the lower end of its 52-week range of $0.5 – $2.64.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

AGEN +411.6%
Agenus Inc.
$126M · P/E 1.4x · Buy
PTN +367.7%
Palatin Technologies, Inc.
$20M · P/E 104.0x · Buy
FBIO +298.6%
Fortress Biotech, Inc.
$92M · P/E 0.9x · Buy
VXRT +488.2%
Vaxart, Inc.
$123M · P/E 3.2x · Buy
PLX +378.3%
Protalix BioTherapeutics, Inc.
$185M · P/E 12.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ELUT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Lake Street — Reiterated
Buy → Buy 2025-09-10 27% win rate (11 calls)
Lake Street — Reiterated
Buy → Buy 2025-05-09 27% win rate (11 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2025-03-07 40% win rate (10 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-11-15 40% win rate (10 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-09-06 40% win rate (10 calls)
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2024-08-08 40% win rate (10 calls)
Lake Street — Reiterated
Buy → Buy 2024-06-21 27% win rate (11 calls)
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2024-06-20 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →